BidaskClub upgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a sell rating to a hold rating in a research note published on Thursday morning.

Several other equities research analysts have also recently weighed in on NKTR. Roth Capital set a $33.00 price target on Nektar Therapeutics and gave the company a buy rating in a research note on Wednesday, August 9th. Zacks Investment Research cut Nektar Therapeutics from a buy rating to a hold rating in a research note on Friday, August 11th. Jefferies Group LLC set a $25.00 price target on Nektar Therapeutics and gave the company a buy rating in a research note on Saturday, April 22nd. HC Wainwright began coverage on Nektar Therapeutics in a research note on Monday, August 7th. They issued a buy rating and a $31.00 price target for the company. Finally, William Blair reissued an outperform rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $26.10.

Shares of Nektar Therapeutics (NKTR) opened at 18.04 on Thursday. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The company has a 50-day moving average price of $20.49 and a 200-day moving average price of $18.57. The firm’s market capitalization is $2.82 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. During the same period in the previous year, the company earned ($0.36) EPS. Nektar Therapeutics’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities analysts forecast that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/21/nektar-therapeutics-nktr-upgraded-to-hold-by-bidaskclub.html.

In other Nektar Therapeutics news, Director Roy A. Whitfield bought 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average price of $17.95 per share, with a total value of $628,250.00. Following the completion of the purchase, the director now directly owns 133,000 shares of the company’s stock, valued at approximately $2,387,350. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO John Nicholson sold 3,177 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $61,379.64. Following the sale, the chief operating officer now directly owns 224,066 shares of the company’s stock, valued at approximately $4,328,955.12. The disclosure for this sale can be found here. Insiders have sold 237,629 shares of company stock valued at $4,820,217 in the last ninety days. 6.10% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in NKTR. Flinton Capital Management LLC boosted its stake in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares in the last quarter. Meadow Creek Investment Management LLC boosted its stake in Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 616 shares in the last quarter. LS Investment Advisors LLC boosted its stake in Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares in the last quarter. Finally, Glen Harbor Capital Management LLC boosted its stake in Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 784 shares in the last quarter. 93.02% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.